Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV

被引:51
作者
Bassett, IV
Freedberg, KA
Walensky, RP
机构
[1] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA
[4] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
关键词
D O I
10.1086/422459
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Thousands of health care workers are potentially exposed to human immunodeficiency virus (HIV) each year via occupationally acquired needlesticks. The Centers for Disease Control and Prevention (Atlanta, GA) advise health care workers who experience a high-risk occupational exposure from an HIV-infected patient to begin receiving multidrug antiretroviral postexposure prophylaxis (PEP) as soon as possible, preferably within 36 h after exposure. Although the need to prescribe antiretroviral postexposure prophylaxis in a timely fashion is common, few data exist regarding the efficacy and optimal regimen for prophylaxis to prevent transmission. Our objectives were to examine the limited human and animal data on postexposure prophylaxis, to elucidate the factors that affect the choice of 2 versus 3 drugs as the optimal prophylactic drug regimen, and to place these findings within a mathematical framework to help guide the prescription of PEP.
引用
收藏
页码:395 / 401
页数:7
相关论文
共 37 条
[1]  
ALEXANDER C, 1999, 6 C RETR OPP INF CHI
[2]   WHY SOME HEALTH POLICIES DONT MAKE SENSE AT THE BEDSIDE [J].
ASCH, DA ;
HERSHEY, JC .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (11) :846-850
[3]  
BALAGUERA H, 2001, 8 INT C ANT AG CHEM
[4]   Postexposure prophylaxis for occupational exposure to HIV [J].
Bangsberg, D ;
Goldschmidt, RH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (17) :1623-1624
[5]  
Bell David M., 1997, American Journal of Medicine, V102, P9, DOI 10.1016/S0002-9343(97)89441-7
[6]   Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1 [J].
Benn, PD ;
Mercey, DE ;
Brink, N ;
Scott, G ;
Williams, IG .
LANCET, 2001, 357 (9257) :687-688
[7]  
Braitstein P, 2002, J ACQ IMMUN DEF SYND, V29, P547
[8]   A case-control study of HIV seroconversion in health care workers after percutaneous exposure [J].
Cardo, DM ;
Culver, DH ;
Ciesielski, CA ;
Srivastava, PU ;
Marcus, R ;
Abiteboul, D ;
Heptonstall, J ;
Ippolito, G ;
Lot, F ;
McKibben, P ;
Bell, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (21) :1485-1490
[9]  
CDC, 2001, Morbidity and Mortality Weekly Report, V50, P1
[10]  
*CDCP, 2000, MMWR-MORBID MORTAL W, V12, P24